Category: PSYCH STOCK NEWS

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

After Dropping 94% From Post IPO high from $19.45, a loss of exceeding $3 billion and change, ATAI is in the early stages of a recovery (our opinion) gaining 94%...

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Trondheim in central Norway will be the location of Awakn's 4th clinic LIVE QUOTE Bargain Hunter's Paradise ?

Silo Pharma (SILO) Issues Letter to Shareholders

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine LIVE QUOTE Bargain Hunters Dream

Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

View Post ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with...

Silo Pharma (SILO) Attends Dawson James Conference.

We watched an excellent presentation from management at the Dawson conference and starting our due diligence now. Primary item of our interest is a joint...

PharmaTher (PHRM, PHRRF) $0.10 Gets $3.80 Price Target From H.C. Wainwright – 37 Times (3,700%) Higher.

Thus, to us, the key potential positive events that could lead to a rerating in PHRM.CN shares include publication of the Phase 2 trial data evaluating ketamine in LID-PD in...

Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

MIAMI, June 03, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will accept delivery of...

Australian Icannex (IHL:ASX) Headed to NASDAQ?

Incannex completes Phase 2 trial for its cannabinoid drug for sleep apnea, flags Nasdaq listing in 2022 With Phase 2 dosing complete,...
Most Popular

Interview: Dr. Deborah Nash, Ibogaine and Miami Based DemeRX.

Partnered with ATAI Life Sciences ATAI. Amazing Interview. "I said there's no way that you can take one dose of Ibogaine...

Psychedelic Marketing: Adrian Morrison

https://youtu.be/EZPAoTFqaro

Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical (BWVI). Forbes

Mike Zapolin, Kevein Harrington and CEO Chad Harman Another Shark Tank original has invested in the psychedelic industry.